Eric L. Sievers - Concepedia

Author

Eric L. Sievers

Also Known As

E L Sievers, E SIEVERS, E Sievers, E. L. Sievers, E. Sievers, E.L. Sievers, EL Sievers, Eric L Sievers, Eric L. Sievers, Eric Sievers

155

Publications

14.4K

Citations

H-Index

Concepts

All Affiliations

Seagen (United States)Fred Hutch Cancer Center The University of Texas MD Anderson Cancer Center University of Washington Sylvester Comprehensive Cancer Center

About

Eric L. Sievers is an author at Seagen (United States) specializing in immunotherapy, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	2K
2	Immunology	10	11	1.2K
3	Health Sciences	3	3	141
4	Cell Biology	3	3	63
5	Cellular Therapies	3	3	810

Eric L. Sievers

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma Anas Younes, Ajay K. Gopal, Scott E. Smith, Journal of Clinical Oncology	2012	1.5K
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas Anas Younes, Nancy L. Bartlett, John P. Leonard, New England Journal of Medicine	2010	1.3K
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Barbara Pro, Ranjana H. Advani, Pauline Brice, Journal of Clinical Oncology	2012	979
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Journal of Clinical Oncology	2001	882
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia Steven L. Soignet, Stanley R. Frankel, Dan Douer, Journal of Clinical Oncology	2001	822
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Peter D. Senter, Eric L. Sievers Nature Biotechnology Tumor BiologyLymphoid NeoplasiaMedicineImmunologyPathology	2012	736
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, The Lancet Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationOncology	2015	726
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate Eric L. Sievers, F R Appelbaum, Ricardo Spielberger, Blood	1999	456
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer, Cancer	2005	451
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate Eric L. Sievers, Frederick R. Appelbaum, Ricardo Spielberger, Blood	1999	437

Page 1